Hadox Research Labs · Science Intelligence
We watch the research landscape, compare papers with fair peers, read the full text and publish the receipts. No journal logo, citation count or model gets the last word alone.
Current truthThe ascendance engine is still building history. This edition is editorially selected, not algorithmically declared “rising.”
Comparison universe1,138 current candidates across 41 age, field and article-type cohorts.
Evidence gateEvery public dossier was read from an authorised full body. Abstract-only records remain ineligible.
As of25 Jul 2026
This public, sanitized index unites the observatory with Hadox's reviewed dossiers. Bibliographic metadata and measured signal states are visible; abstracts and source text are not.
Tracking is not endorsement. A row means Hadox is monitoring the paper or has completed a public dossier. Radar states appear only when measured against age-, field- and article-type peers; no metric is invented for editorial selections.
Read the selection method| Paper | Field | Radar state | Attention | Next review | Hadox |
|---|---|---|---|---|---|
| Mitochondrial control of glycerolipid synthesis by a PEP shuttle Cell · 2026-05-01 · 10.1016/j.cell.2026.02.017 | Biochemistry, Genetics and Molecular Biology Research article | Baseline Candidate · 1 signal point | 4 citations Cohort 95% · 31 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Multi-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome Cell · 2026-05-01 · 10.1016/j.cell.2026.03.049 | Biochemistry, Genetics and Molecular Biology Research article | Baseline Candidate · 1 signal point | 1 citations Cohort 69% · 31 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Nancy J Cox The Lancet · 2026-05-01 · 10.1016/s0140-6736(26)00928-1 | Medicine Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 30% · 65 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges Cell · 2026-05-01 · 10.1016/j.cell.2026.04.016 | Oncology Research article | Baseline Candidate · 1 signal point | 2 citations Cohort 33% · 6 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Nuclear envelope budding enables export of large transcripts in muscle cells Cell · 2026-05-01 · 10.1016/j.cell.2026.03.050 | Molecular Biology Research article | Baseline Candidate · 1 signal point | 1 citations Cohort 58% · 19 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Offline: Ten lessons for women's and children's health The Lancet · 2026-05-01 · 10.1016/s0140-6736(26)00801-9 | Public Health, Environmental and Occupational Health Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 17% · 6 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Offline: The dishonest politics of global health The Lancet · 2026-05-01 · 10.1016/s0140-6736(26)01039-1 | Public Health, Environmental and Occupational Health Research article | Baseline Candidate · 1 signal point | 1 citations Cohort 50% · 6 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Outcome measure limitations in the SCIENCE trial The Lancet · 2026-05-01 · 10.1016/s0140-6736(26)00697-5 | Social Sciences Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 35% · 20 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Pastoral care and unmet need in acute mental health services The Lancet · 2026-05-01 · 10.1016/s0140-6736(26)00688-4 | Social Sciences Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 40% · 10 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Physiological brain clearance architecture revealed by neuronal protein tracing Cell · 2026-05-01 · 10.1016/j.cell.2026.04.048 | Neuroscience Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 33% · 9 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Plasma biomarkers for Alzheimer's disease among middle-aged individuals The Lancet · 2026-05-01 · 10.1016/s0140-6736(26)00692-6 | Medicine Research article | Baseline Candidate · 1 signal point | 1 citations Cohort 66% · 65 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Prasinezumab: what have we learned from PASADENA and PADOVA? The Lancet · 2026-05-01 · 10.1016/s0140-6736(26)00985-2 | Biochemistry, Genetics and Molecular Biology Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 31% · 31 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Predicting competition and substrate preferences for targeted microbiome alteration Cell · 2026-05-01 · 10.1016/j.cell.2026.03.036 | Social Sciences Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 40% · 10 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Pyruvate is a natural suppressor of interferon signaling by inducing STAT1 protein pyruvylation Cell · 2026-05-01 · 10.1016/j.cell.2026.04.018 | Immunology Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 44% · 8 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Rational design of Gi-biased CB1 agonist with reduced side effects Cell · 2026-05-01 · 10.1016/j.cell.2026.03.020 | Medicine Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 30% · 65 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
These are the exact visual editions already shared by Hadox. Each one now has a canonical source, immutable assets and a visible workflow state; publication history never substitutes for scientific review.
01
The source is identified, but no authorised full body is available for Hadox review yet.
02
Published edition linked to a full-text Hadox evidence dossier.
03
This official-source story is awaiting the institutional evidence workflow.
Historical copy retained; correction logged in the workflow.
Today, 0 papers have enough history for a momentum score and 0 public dossiers were selected by an open ascendance gate. That is not a failure to hide; it is the calibration state.
current paper assessments from Crossref + Openalex
cohorts split by paper age, article type and discipline
baseline · 1 watch · 0 rising
01Observe attention against fair peers.
02Wait for enough history to measure velocity.
03Read the authorised full paper and map every claim.
04Make a separate editorial decision and publish the evidence.